Submitted by web@researchtop... on Mon, 05/16/2011 - 10:13
In April, RTP convened a Working Group of multiple myeloma (MM) clinical investigators, practicing hematologists/oncologists and oncology nurse practitioners (click here to see full faculty) to better elucidate current practice patterns in the management of this disease. The event featured a mix of didactic lectures, moderated, case-based discussions and extensive, real-time polling of the group intended to capture the preferred treatment strategies for a number of clinical scenarios.
The eight topic modules below — introduced sequentially via weekly emails over the next two months — provide access to the recorded discussions and conclusions that emerged from the event and are presented in the following formats (click here to view the the audio proceedings from this meeting):
- Treatment Preference Matrix — Graphical summary of the investigators' preferred
management approaches for four distinct clinical scenarios, including text-based
commentary from select investigators. - Dr Love's Email — Full-text version of the summary email promoting each topic module.
- Video Clip from MM Working Group — Short video segment featuring moderated panel discussion related to the topic module.
- Video Presentations — Mini-lecture with slides by invited clinical investigators related to the topics discussed.
Workup, Risk Stratification and Pretransplant Induction Therapy
- Treatment Preference Matrix
- Dr Love's Email
- Video Clip from MM Working Group - Case discussion
of a 40-year-old woman with ISS Stage I, standard-risk
MM - Video Presentations
- Nikhil C Munshi, MD — Workup and Risk Stratification
- Sagar Lonial, MD — Risk Assessment in the Relapse Setting
- Guido Tricot, MD, PhD — Induction Treatment for Younger Transplant-Ineligible Patients
Management of Side Effects and Toxicities of Systemic Treatment
- Treatment Preference Matrix
- Dr Love's Email
- Video Clip from MM Working Group - Clinical
investigator discussion on the use of subcutaneous
bortezomib - Video Presentations
- Ivan Borrello, MD — Bortezomib-Associated Neuropathy
- Jeffrey A Zonder, MD — Systemic Agents' Toxicities/Side Effects
Bone-Targeted Treatment
- Treatment Preference Matrix
- Dr Love's Email
- Video Clip from MM Working Group - MRC IX trial:
Questions and controversies - Video Presentations
- Melissa Alsina, MD — Bone-Targeted Treatment
- Cristina Gasparetto, MD — Scheduling of Bone-Targeted Agents
- David S Siegel, MD, PhD — Vertebroplasty and XRT
Special Cases
- Dr Love's Email
- Video Clips from MM Working Group
Faculty presentations and discussions of 7 patient cases: - 70 yo man with amyloidosis and macroglossia
- 95 yo woman with CHF and MM
- 80 yo woman with plasma cell leukemia
- 47 yo woman with MGUS
- 65 yo woman with MGUS
- 47 yo woman with smoldering myeloma
- 67 yo man with nonsecretory myeloma
- Video Presentation
- Carol Ann Huff, MD — Nutritional Support and Palliative Care
Method of Transplant and Post-Transplant Maintenance
- Treatment Preference Matrix
- Dr Love's Email
- Video Clip from MM Working Group - Case discussion
of a 67-year-old man with IgA myeloma with
hypodiploidy and del(13q) - Video Presentations
- Ravi Vij, MD — Post-Transplant Maintenance Therapy
- William I Bensinger, MD — Delayed Transplantation
- Edward A Stadtmauer, MD — Allo- and Tandem Transplantation
New Agents in Development
- Treatment Preference Matrix
- Dr Love's Email
- Video Clip from MM Working Group - Discussion of
novel agents carfilzomib and pomalidomide - Video Presentations
- Rafael Fonseca, MD — New Agents in Development
- Kenneth C Anderson, MD — Access to Trials in the Community Setting
Induction Treatment and Maintenance Therapy for Patients Not Eligible for Transplant
- Treatment Preference Matrix
- Dr Love's Email
- Video Clip from MM Working Group - Discussion of
induction therapies for the elderly and dose reductions - Video Presentations
- Antonio Palumbo, MD — Induction Therapy for Older Patients
- A Keith Stewart, MBChB — Postinduction Maintenance
- Morie A Gertz, MD — 60-80 yo with Adverse Cytogenetics
- Jeffrey L Wolf, MD — 60-80 yo with Normal Cytogenetics
Management of Patients with Renal Failure
- Treatment Preference Matrix
- Dr Love's Email
- Video Clips from MM Working Group
Faculty presentations and discussions of 3 patient cases: - 50 yo man with renal failure and hypercalcemia
- 59 yo woman with renal compromise and bone disease
- 60 yo man refuses blood products due to religious beliefs
- Video Presentation
- Ruben Niesvizky, MD — Induction Therapy for Older Patients with Comorbidities